The IV drug, created by Japanese drugmaker Eisai, is covered by Medicare and deemed safe and effective for patients with mild dementia and other symptoms caused by early Alzheimer's.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
